27August

Novo Nordisk to acquire Calibrium LLC and MB2 LLC ... Read more

26August

Novo Nordisk plans 2 billion US dollar investment in new production facilities i ... Read more

26August

Novo Nordisk to initiate phase 3a development of oral semaglutide, a once-daily ... Read more

24August

Novo Nordisk completes second and final phase 3a trial with liraglutide as adjun ... Read more

26August

Novo Nordisk to initiate phase 3a development of oral semaglutide, a once-daily ... Read more

24August

Novo Nordisk completes second and final phase 3a trial with liraglutide as adjun ... Read more

24August

Novo Nordisk A/S - Share repurchase programme ... Read more

17August

Novo Nordisk A/S - Share repurchase programme ... Read more

18September

Kepler Cheuvreux Conference, Paris

18September

Merrill Lynch Global Healthcare Conference, London

21September

Investor Event Sydbank, Århus

30September

Bernstein Strategic Decision Conference, London

 

 

 

Investors

 
Share information


Take an advanced view of the Novo Nordisk share

 
IR material


Download relevant Investor Relations material

 
Q2 results


See information on the Q2 release



Novo Nordisk at a glance


Private shareholders


See relevant content for private investors



Annual report


Download the Novo Nordisk Annual Report



Contacts



Subscriptions


Sign up and follow Novo Nordisk Investors Relations



Recent event


See information on the ADA 2015 investor and analyst even